US biotech Gilead Sciences (Nasdaq: GILD) was trading more than 1% higher by early afternoon Thursday.
The company had earlier announced week 48 results from the pivotal Phase III trial evaluating Hepcludex (bulevirtide) for the treatment of chronic hepatitis delta virus (HDV) infection.
Findings from the study underscore the efficacy and safety of the first-in-class entry inhibitor for the treatment of chronic HDV. They were presented in the International Liver Congress (ILC) 2022 Official Press Program.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze